Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.42 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | KDM6B | O15054 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5827069 | 0.85 | KDM4C (0.46) | KDM4CKDM4DKDM6BKDM4EKDM4A | |
| SCHEMBL3787548 | 0.83 | CA1 (0.49) | KDM4CKDM4DKDM4EMEN1ALDH1A1 | |
| SCHEMBL13740469 | 0.82 | KDM4D (0.65) | KDM4CKDM4DKDM4EALDH1A1KMT2A | |
| SCHEMBL28824138 | 0.81 | KDM4E (0.53) | KDM4CKDM4DTDP1KDM6BKDM4E | |
| SCHEMBL8688740 | 0.79 | MDM4 (0.45) | MAPTL3MBTL1MDM2 | |
| SCHEMBL3899443 | 0.79 | TSHR (0.48) | KDM4EMAPTL3MBTL1NPC1RAB9A | |
| SCHEMBL19255633 | 0.79 | CYP1A2 (0.50) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL1043517 | 0.78 | KDM4C (0.46) | KDM4CKDM4DTDP1KDM6BMEN1 | |
| SCHEMBL30908198 | 0.78 | HDAC1 (0.66) | TDP1ALDH1A1MAPTL3MBTL1HDAC3 | |
| SCHEMBL15017796 | 0.77 | RAB9A (0.45) | KDM4CRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20230374006-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-11-23 | — | — | US | disclosed |
| CN-112384517-B | Heteroaryl compounds and uses thereof | 新旭生技股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20230047178-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | APRINOIA THERAPEUTICS INC. (CN) | 2023-02-16 | — | — | US | disclosed |
| US-20210253569-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | APRINOIA THERAPEUTICS INC. (CN) | 2021-08-19 | — | — | US | disclosed |
| EP-3790883-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | Aprinoia Therapeutics Inc. (TW) | 2021-03-17 | — | — | EP | disclosed |
| US-20200317666-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2020-10-08 | — | — | US | disclosed |
| US-10717733-B2 | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | PHARMAXIS LTD. (AU) | 2020-07-21 | — | — | US | disclosed |
| WO-2019214681-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | APRINOIA THERAPEUTICS INC. (CN) | 2019-11-14 | — | — | WO | disclosed |
| US-20190040007-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | PHARMAXIS LTD. (AU) | 2019-02-07 | — | — | US | disclosed |
| EP-3154974-A1 | TRICYCLIC COMPOUNDS AS ALPHA- 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2017-04-19 | — | — | EP | disclosed |
| CN-105358558-A | Diazacarbazole derivatives as tau-pet-ligands | HOFFMANN LA ROCHE | 2016-02-24 | — | — | CN | disclosed |
| CN-103502237-B | Faah inhibitor | IRONWOOD PHARMACEUTICALS, INC. (US) | 2016-01-20 | — | — | CN | disclosed |
| WO-2015191401-A1 | TRICYCLIC COMPOUNDS AS ALPHA- 7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-17 | — | — | WO | disclosed |
| CN-100439367-C | Substituted 1H-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase lepsilon | AVENTIS PHARMA INC (US) | 2008-12-03 | — | — | CN | disclosed |
| CN-1906194-A | Substituted 1H-pyrrolo [3, 2-b, 3, 2-c and 2, 3-c ] pyridine-2-carboxamides and related analogs as inhibitors of casein kinase ie | AVENTIS PHARMA INC (US) | 2007-01-31 | — | — | CN | disclosed |
| US-6825191-B2 | ANTICOAGULANT | AJINOMOTO CO., INC. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20030186969-A1 | Benzodiazepine derivatives | AJINOMOTO CO. INC (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1329450-A1 | BENZODIAZEPINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2003-07-23 | — | — | EP | disclosed |
| CN-1291892-A | Substituted oxoazaheterocyclyl factor Xa inhibitors | AWENTIS PHARMACEUTICAL INC (US) | 2001-04-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374006-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | MAPT, APP, SLCO1B3 | KDM4C 4630/4885KDM4D 4600/4885TDP1 765/4885 |
| US-10717733-B2 | Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof | IDO1, IDO2, INMT | KDM4C 501/4885KDM4D 334/4885TDP1 1426/4885 |
| US-20030186969-A1 | Benzodiazepine derivatives | GABRA1, F11, GABRA4 | KDM4C 2067/4885KDM4D 1265/4885TDP1 2357/4885 |
| US-20210253569-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | MAPT, APP, SLCO1B3 | KDM4C 4630/4885KDM4D 4600/4885TDP1 765/4885 |
| US-20190040007-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | IDO1, IDO2, INMT | KDM4C 501/4885KDM4D 334/4885TDP1 1426/4885 |
| US-20230047178-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | MAPT, APP, SLCO1B3 | KDM4C 4630/4885KDM4D 4600/4885TDP1 765/4885 |
| US-20200317666-A1 | HALOALLYLAMINE INDOLE AND AZAINDOLE DERIVATIVE INHIBITORS OF LYSYL OXIDASES AND USES THEREOF | IDO1, IDO2, INMT | KDM4C 501/4885KDM4D 334/4885TDP1 1426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.